Chemical formula: C₉₀H₁₂₀N₂₀O₂₂S₂ Molecular mass: 1,896.833 g/mol PubChem compound: 162462321
Icotrokinra interacts in the following cases:
No data on the response to immunisations under icotrokinra treatment are available. As a precautionary measure, prior to treatment initiation, completion of all age-appropriate immunisations according to the current immunisation guidelines should be considered. Administration of live vaccines is not recommended during treatment with icotrokinra and within 3 days after discontinuation of icotrokinra.
Icotrokinra has not been studied in patients with end-stage renal disease and should only be used in these patients if the benefit outweighs the possible risk.
There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of icotrokinra in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.
As a precautionary measure, it is preferable to avoid the use of icotrokinra during pregnancy.
It is unknown if icotrokinra crosses the placenta. As a precautionary measure, administration of live vaccines to newborns potentially exposed to icotrokinra during pregnancy within the first 3 days after birth is not recommended. If there is a clear clinical benefit for the individual infant, administration of a live vaccine might be considered.
It is unknown whether icotrokinra/metabolites are excreted in human milk. Available pharmacokinetic data in animals have shown the presence of icotrokinra in the plasma of nursing rat pups. A risk to the newborn/infant cannot be excluded. A decision must be made whether to discontinue breast-feeding or discontinue/abstain from icotrokinra therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
The effect of icotrokinra on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility.
Icotrokinra has no or negligible influence on the ability to drive and use machines.
The most frequently reported adverse reactions were fungal infections (1.1%).
Adverse reactions for icotrokinra from clinical studies are listed (see table) by MedDRA System Organ Class and are based on the following conventions: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000) and not known (cannot be estimated from the available data).
List of adverse reactions:
| System Organ Class | Frequency | Adverse reaction |
| Infections and infestations | Common | Fungal infectionsa |
| Uncommon | Diverticulitis |
a Fungal infections include tinea pedis (n=4), tinea versicolor (n=2), oral candidiasis (n=2), onychomycosis (n=1), skin candida (n=1), urinary tract candidiasis (n=1), vulvovaginal candidiasis (n=1), fungal skin infection (n=1), genital infection fungal (n=1), ear infection fungal (n=1), and laryngitis fungal (n=1).
A total of 72 paediatric patients 12 to less than 18 years of age have been treated with icotrokinra 200 mg orally once daily in two clinical studies in moderate to severe plaque psoriasis. Of these, 71 patients were exposed to icotrokinra for at least 6 months and 67 patients were exposed to icotrokinra for at least one year. The safety profile in adolescents was consistent with the safety profile observed in the overall study population.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.